drugset
drugset / Trial / NCT04570436

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

NCT04570436 ↗

Phase 4 Completed 52 enrolled Viatris Specialty LLC
RandomizedCrossoverQuadruple-blindOther

Summary

This will be a randomized, double-blind, double-dummy, placebo- and active controlled, 5 treatment, 10 sequence, 5 period crossover single dose, Williams square design study in healthy adult, non drug dependent male and female participants with drug abuse experience with sedative drugs.

Timeline

Start
2021-03-29
Primary completion
2022-11-10
Completion
2022-11-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diazepam Small molecule 20 mg Oral
Subject Gabapentin Small molecule 600 mg Oral
Subject Gabapentin Small molecule 1200 mg Oral
Subject Gabapentin Small molecule 1800 mg Oral

Indications

substance abuse